Sativex®: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 5, 2006, Pages 607-615

  Barnes, Michael Philip ^a  

^a Hunters Moor Regional Rehabilitation Centre   (United Kingdom)

Author keywords

Cannabis; Multiple sclerosis; Neuropathic pain; Sativex ; Spasticity

Indexed keywords

11 HYDROXYDRONABINOL; BACLOFEN; CANNABIDIOL; CANNABIS; DANTROLENE; DRONABINOL; PLACEBO; TETRAHYDROCANNABINOL; TIZANIDINE; ANALGESIC AGENT; CANNABINOID; PLANT EXTRACT; TETRAHYDROCANNABINOL CANNABIDIOL COMBINATION; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ADD ON THERAPY; AEROSOL; ANXIETY DISORDER; APPLICATION SITE PAIN; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BALANCE IMPAIRMENT; CANADA; CLINICAL TRIAL; CONFUSION; DIARRHEA; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUNKENNESS; DYSGEUSIA; EMOTION; EMOTIONAL DISORDER; EUPHORIA; FATIGUE; HALLUCINATION; HUMAN; ILLUSION; LETHARGY; LEUKOPLAKIA; MEMORY DISORDER; MENTAL DISEASE; MOOD CHANGE; MOUTH DISCOMFORT; MOUTH PAIN; MOUTH ULCER; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEUROPATHIC PAIN; ORAL MUCOSAL DISEASE; ORTHOSTATIC HYPOTENSION; PARANOIA; PRESCRIPTION; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SYNCOPE; TOOTH DISCOLORATION; VOMITING; WEAKNESS; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG SELF ADMINISTRATION; PAIN; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER;

ANALGESICS; CANNABINOIDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; SELF ADMINISTRATION; SLEEP DISORDERS;

EID: 33645816506     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.5.607     Document Type: Article

References (28)

1. RICE GPA, INCORVAIA B, MUNARI L et al.: Interferon relapsing remitting multiple sclerosis. Cochrane Database Syst. Rev. (2001) 4:CD002002.
2. KRAFT GH, FREAL JE, CORYLL JK: Disability disease duration and rehabilitation service needs in multiple sclerosis: patient perspectives. Arch. Phys. Med. Rehabil. (1986) 67:164-178.
3. SAARTO T, WIFFEN PJ: Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. (2005) 3:CD005454.
4. HOWLETT AC, BARTH F, BONNER TI et al.: International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54(2):161-202.
5. PERTWEE RG: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther.(1997) 74:129-180.
6. PERTWEE RG: Cannabinoid receptors and pain. Prog. Neurobiol. (2001) 63:569-611.
7. WHITTLE BA, GUY GW: Development of cannabis-based medicines: risk, benefit and serendipity. In: The medicinal use of cannabis and cannabinoids. Guy GW, Whittle BA, Robson PJ (Eds). Pharmaceutical Press, London, UK (2004):427-466.
8. MCPARTLAND JM, RUSSO EB: Cannabis and cannabis extracts: greater than the sum of their parts? J. Cannabis Therapeutics (2001) 1(3-4):103-132.
9. EL SOHLY MA: Chemical constituents of cannabis. In: Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. Grotenhermen F, Russo E (Eds). Haworth Press, New York, US (2002):27-36.
10. DE MEIJER E: The breeding of cannabis cultivars for pharmaceutical end uses. In: The medicinal use of cannabis and cannabinoids. Guy GW, Whittle BA, Robson PJ (Eds). Pharmaceutical Press, London, UK (2004):55-69.
11. WARE MA, ADAMS H, GUY GW: The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract. (2005) 59:291-295.
12. ROBSON P: Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry (2001) 178:107-115.
13. MCPARTLAND JM, PRUITT PL: Medicinal marijuana and its use by the immunocompromised. Altern. Ther. Health Med. (1997) 3:39-45.
14. TASHKIN DP: Smoked marijuana as a cause of lung injury. Monald Arch. Chest Dis. (2005) 63:93-100.
15. ROBSON P: Cannabis as medicine: time for the phoenix to arise? Br. Med. J. (1998) 316:1034-1035.
16. PERTWEE RG: Pharmacological and therapeutic targets for delta-9-tetrahydrocannabinol and cannabidiol. Euphytica (2004) 140:73-82.
17. PERTWEE RG: The pharmacology and therapeutic potential of cannabidiol. In: Cannabinoids. Di Marzo V (Ed.). Kluwer Academic/Plenum Publishers, New York, US (2004):32-83.
18. BORNHEIM LM, LASKER JM, RAUCY JL: Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab. Dispos. (1992) 20(2):241-246.
19. HAWKSWORTH GM, MCARDLE KE: Metabolism and pharmacokinetics of cannabinoids. In: The Medicinal Uses of Cannabis and Cannabinoids. Guy GW, Whittle BA, Robson PJ (Eds). Pharmaceutical Press, London, UK (2004):205-228.
20. HUESTIS MA: Pharmacokinetics and metabolism of the plant cannabinoids, delta-9-tetrahydrocannabinol, cannabidiol and cannabinol. In: Cannabinoids. Pertwee RG (Ed.). Springer-Verlag, Heidelberg, Germany (2005) 168:657-690.
21. ELLIS GM, MANN MA, JUDSON BA et al.: Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin. Pharmacol. Ther. (1985) 38:572-578.
22. HARVEY DJ, MECHOULAM R: Metabolites of cannabidiol identified in human urine. Xenobiotica (1990) 20:303-320.
23. WADE DT, MAKELA P, ROBSON P et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. (2004) 10:434-441.
24. ZAJICEK J, FOX P, SANDERS H et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomized, plcacebo controlled trial. Lancet (2003) 362:1517-1526.
25. PANDYAN AD, JOHNSON GR, PRICE CIM et al.: A review of the properties and limitations of the Ashworth & modified Ashworth Scales as measures of spasticity. Clin. Rehabil. (1999) 13:373-383.
26. PANDYAN AD, PRICE CIM, BARNES MP, JOHNSON GR: A biomechanical investigation into the validity of the modified Ashworth Scale as a measure of elbow spasticity. Clin. Rehabil. (2003) 17:290-294.
27. ROG DJ, NURMIKKO TJ, FRIEDE T, YOUNG CA: Randomized controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology (2005) 65:812-819.
28. NICHOLSON AN, TURNER C, STONE BM, ROBSON PJ: Effect of Delta-9- tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J. Clin. Psychopharmacol. (2004) 24:305-313.